DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. Read More

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: